| 1 |
28293857 | Effect of cilostazol in treating diabetes-associated microvascular complications. | 2017 May |
1 |
| 2 |
21756880 | Cilostazol reduces MCP-1-induced chemotaxis and adhesion of THP-1 monocytes by inhibiting CCR2 gene expression. | 2011 Jul 29 |
6 |
| 3 |
18703532 | Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. | 2009 Jan 1 |
2 |
| 4 |
17516547 | Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells. | 2008 Jan 1 |
1 |
| 5 |
19967051 | Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells. | 2008 Aug |
2 |
| 6 |
15525793 | Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. | 2005 Mar |
1 |
| 7 |
9405974 | Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. | 1997 Oct |
1 |